Danaher shares climb as analysts turn more constructive after Q1 guidance lift

Danaher Corporation (DHR) is up 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks driven by a rebound in sentiment after recent weakness, helped by fresh analyst commentary that nudged price targets higher and kept bullish ratings intact. Investors also continue to digest Danaher’s Q1 results, where adjusted EPS beat expectations and full-year adjusted EPS guidance was increased.

Details:

After the company’s first-quarter update, Danaher maintained its full-year core revenue growth outlook while increasing its full-year adjusted diluted net EPS range.

Recent analyst actions have included price-target increases while keeping positive ratings, which can act as a near-term catalyst when a stock has been under pressure.

Danaher’s pending agreement to acquire Masimo for $180 per share in cash (about $9.9 billion enterprise value) remains a major strategic focus, with investors weighing portfolio positioning in diagnostics.

This could also reflect a broader rotation back into large-cap healthcare and life-science tools following an oversold period for the group.

Sources:

Danaher Investor Relations, Nasdaq, TipRanks

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DHR Insider Trading Activity

$DHR insiders have traded $DHR stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.

Here’s a breakdown of recent trading of $DHR stock by insiders over the last 6 months:

MITCHELL P RALES (Chairman of Exec. Committee) has made 0 purchases and 2 sales selling 40,625 shares for an estimated $9,359,066.
TERI LIST sold 3,298 shares for an estimated $746,997
GREGORY M MILOSEVICH (Executive Vice President) sold 1,320 shares for an estimated $274,574
ALAN G SPOON sold 1,358 shares for an estimated $237,206

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive DHR Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$DHR Hedge Fund Activity

We have seen 926 institutional investors add shares of $DHR stock to their portfolio, and 1,252 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL RESEARCH GLOBAL INVESTORS added 8,322,198 shares (+1445.9%) to their portfolio in Q1 2026, for an estimated $1,556,583,913
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 5,739,048 shares (-87.3%) from their portfolio in Q4 2025, for an estimated $1,313,782,868
CAPITAL INTERNATIONAL INVESTORS removed 4,231,295 shares (-23.2%) from their portfolio in Q1 2026, for an estimated $791,421,416
HOLOCENE ADVISORS, LP added 3,099,516 shares (+329.9%) to their portfolio in Q1 2026, for an estimated $579,733,472
FMR LLC added 3,027,600 shares (+15.5%) to their portfolio in Q1 2026, for an estimated $566,282,304
JPMORGAN CHASE & CO added 2,943,496 shares (+15.8%) to their portfolio in Q4 2025, for an estimated $673,825,104
VIKING GLOBAL INVESTORS LP removed 2,751,245 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $629,815,005

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DHR Government Contracts

We have seen $132,177,547 of award payments to $DHR over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

IN-VITRO REAGENTS - VISN 15, ORDERING PERIOD ONE: $2,952,609
MICROBIOLOGY REAGENTS & CONSUMABLES ADD CLAUSE 852.222-71 - COMPLIANCE WITH EXECUTIVE ORDER 13899: $2,353,640
MRSA REAGENTS: $1,884,422

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$DHR Congressional Stock Trading

Members of Congress have traded $DHR stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $DHR stock by members of Congress over the last 6 months:

REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 12/18.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$DHR Analyst Ratings

Wall Street analysts have issued reports on $DHR in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

JP Morgan issued a "Overweight" rating on 01/29/2026
Jefferies issued a "Buy" rating on 01/29/2026
Goldman Sachs issued a "Buy" rating on 12/09/2025

To track analyst ratings and price targets for $DHR, check out Quiver Quantitative's $DHR forecast page.

$DHR Price Targets

Multiple analysts have issued price targets for $DHR recently. We have seen 12 analysts offer price targets for $DHR in the last 6 months, with a median target of $240.0.

Here are some recent targets:

Dan Leonard from RBC Capital set a target price of $200.0 on 05/15/2026
Kallum Titchmarsh from Morgan Stanley set a target price of $255.0 on 04/23/2026
Subbu Nambi from Guggenheim set a target price of $235.0 on 04/22/2026
Catherine Schulte from Baird set a target price of $245.0 on 04/22/2026
Brandon Couillard from Wells Fargo set a target price of $212.0 on 04/22/2026
Dan Leonard from UBS set a target price of $250.0 on 04/22/2026
Luke Sergott from Barclays set a target price of $230.0 on 04/14/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.